What is targeted therapy?

Journal of Clinical Oncology

Volumn 23, Issue 8, 2005, Pages 1614-1615

  Sledge Jr , George W ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEFITINIB; IMATINIB; TAMOXIFEN; TRASTUZUMAB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CISPLATIN;

BREAST CANCER; CANCER CHEMOTHERAPY; COLORECTAL CANCER; DISEASE MARKER; DRUG ACTIVITY; DRUG EFFICACY; EDITORIAL; GENE MUTATION; HUMAN; LUNG CANCER; PRIORITY JOURNAL; PROTEIN TARGETING; BREAST TUMOR; DRUG DELIVERY SYSTEM; FEMALE; MALE; NOTE; TESTIS TUMOR;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CISPLATIN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; TESTICULAR NEOPLASMS;

EID: 15544389968     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.016     Document Type: Editorial

References (6)

1. Pegram MD, Pietras R, Bajamonde A, et al: Targeted therapy: Wave of the future. J Clin Oncol 23:1776-1781, 2005
2. Schneider BP, Miller KD: Angiogenesis of breast cancer. J Clin Oncol 23:1782-1790, 2005
3. Heidelberger C, Chandhari N: Fluorinated pyrimidines: A new class of tumor inhibitory compounds. Nature 179:663-665, 1957
4. Druker B: Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91:1-30, 2004
5. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
6. Paik S, Shak S, Tang G, et al: Expression of the 21 genes in the Recurrence Score assay and prediction of clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP study B-20. Breast Cancer Res Treat 88:515, 2004 (abstr 24)